Andrea M Yeung, Jingtong Huang, Ambarish Pandey, Ibrahim A Hashim, David Kerr, Rodica Pop-Busui, Connie M Rhee, Viral N Shah, Lia Bally, Antoni Bayes-Genis, Yong Mong Bee, Richard Bergenstal, Javed Butler, G Alexander Fleming, Gregory Gilbert, Stephen J Greene, Mikhail N Kosiborod, Lawrence A Leiter, Boris Mankovsky, Thomas W Martens, Chantal Mathieu, Viswanathan Mohan, Kershaw V Patel, Anne Peters, Eun-Jung Rhee, Giuseppe M C Rosano, David B Sacks, Yader Sandoval, Jane Jeffrie Seley, Oliver Schnell, Guillermo Umpierrez, Kayo Waki, Eugene E Wright, Alan H B Wu, David C Klonoff
Diabetes Technology Society assembled a panel of clinician experts in diabetes, biomarker screening, and heart failure to review the current evidence on biomarker screening of people with diabetes (PWD) for heart failure (HF), who are, by definition, at risk for HF (Stage A HF). This consensus report reviews features of HF in PWD from the perspectives of 1) epidemiology, 2) classification of stages, 3) pathophysiology, 4) biomarkers for diagnosing, 5) biomarker assays, 6) diagnostic accuracy of biomarkers, 7) benefits of biomarker screening, 8) consensus recommendations for biomarker screening, 9) stratification of Stage B HF, 10) echocardiographic screening, 11) management of Stage A and Stage B HF, and 12) future directions...
May 11, 2023: Progress in Cardiovascular Diseases